Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Arvinas Inc (Arvinas) is a biopharmaceutical company that develops protein degradation therapeutics. The company pipeline products include Vepdegestrant (ARV-471) which treats metastatic breast cancer; ARV-102 for Parkinson’s disease and progressive supranuclear palsy; ARV-027 which targets spinal-bulbar muscular atrophy; ARV-393 treats non-hodgkin lymphoma; ARV-6723 targets advanced solid tumors; ARV-806 for pancreatic cancer, colorectal cancer and non-small cell lung cancer; and Luxdegalutamide for prostate cancer. It utilizes PROTAC (proteolysis-targeting chimera) discovery engine designed to harness the body's natural protein disposal system to selectively degrade disease-causing proteins. Arnivas is headquartered in New Haven, Connecticut, the US.
Headquarters
United States of America
Address
5 Science Park, 395 Winchester Avenue, New Haven, Connecticut, 06511
Website
www.arvinas.com
Telephone
1 203 5351456
No of Employees
246
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
ARVN (NASD)
Revenue (2024)
$262.6M
-0.3%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
59.4%
(2024 vs 2023)
Market Cap*
$541.3M
Net Profit Margin (2024)
XYZ
59.3%
(2024 vs 2023)
* As of and is in US$
Arvinas Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Pipeline | VEPPANU |
| Vepdegestrant (ARV-471): Metastatic Breast Cancer | |
| ARV-102: | |
| XYZ | |
| XYZ | |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2026 | Regulatory Approval | In May, the company secured US FDA approval for VEPPANU (vepdegestrant) to treat ESR1-mutated, ER+/HER2- advanced breast cancer. |
| 2024 | Contracts/Agreements | In April, the company entered into an agreement with Novartis to develop and commercialize ARV-766, Arvinas’ second-generation PROTAC androgen receptor degrader designed for individuals with prostate cancer. |
| 2023 | Contracts/Agreements | In July, the company and Pfizer announced a clinical trial collaboration and supply agreement with Carrick Therapeutics for execution of a Phase 1b/2 clinical trial to evaluate the novel combination of Carrick’s samuraciclib (CT7001). |
Competitor Comparison
| Key Parameters | Arvinas Inc | AbbVie Inc | AstraZeneca Plc | Novartis AG | Sanofi |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United Kingdom | Switzerland | France |
| City | New Haven | North Chicago | Cambridge | Basel | Paris |
| State/Province | Connecticut | Illinois | Cambridgeshire | Basel-Stadt | Ile-de-France |
| No. of Employees | 246 | 57,000 | 96,100 | 75,267 | 76,493 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Briggs Morrison, M.D. | Chairman | Executive Board | 2026 | 67 |
| Randy Teel, Ph.D. | Chief Executive Officer; Director; President | Executive Board | 2026 | 47 |
| Andrew Saik | Treasurer; Chief Financial Officer | Senior Management | 2024 | 56 |
| Noah Berkowitz, M.D., Ph.D | Chief Medical Officer | Senior Management | 2024 | 62 |
| Angela Cacace, Ph.D | Chief Scientific Officer | Senior Management | 2024 | 58 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer